Association between low fetal fraction in cell‐free DNA testing and adverse pregnancy outcome: A systematic review

Low fetal fraction (LFF) in prenatal cell‐free DNA (cfDNA) testing is an important cause of test failure and no‐call results. LFF might reflect early abnormal placentation and therefore be associated with adverse pregnancy outcome. Here, we review the available literature on the relationship between LFF in cfDNA testing and adverse pregnancy outcome.

[1]  Yunwei Wang,et al.  Factors associated with obtaining results on repeat cell-free DNA testing in samples redrawn due to insufficient fetal fraction , 2020, The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians.

[2]  Huiyan Wang,et al.  Association between low fetal fraction of cell free DNA at the early second-trimester and adverse pregnancy outcomes. , 2020, Pregnancy hypertension.

[3]  S. Sørensen,et al.  Noninvasive prenatal testing and maternal obesity: A review , 2020, Acta obstetricia et gynecologica Scandinavica.

[4]  D. Bianchi,et al.  Fetal fraction and noninvasive prenatal testing: What clinicians need to know , 2019, Prenatal diagnosis.

[5]  P. Roberts,et al.  Low Fetal Fraction and Birth Weight in Women with Negative First-Trimester Cell-Free DNA Screening , 2019, American Journal of Perinatology.

[6]  D. Oepkes,et al.  TRIDENT-2: National Implementation of Genome-Wide Non-Invasive Prenatal Testing as a First-Tier Screening Test in the Netherlands. , 2019, American journal of human genetics.

[7]  Yongjun Zhao,et al.  Prospective head-to-head comparison of accuracy of two sequencing platforms for screening for fetal aneuploidy by cell-free DNA: the PEGASUS study , 2019, European Journal of Human Genetics.

[8]  M. Hacker,et al.  Low fetal fraction of cell-free DNA predicts placental dysfunction and hypertensive disease in pregnancy. , 2019, Pregnancy hypertension.

[9]  D. Rolnik,et al.  Association between fetal fraction on cell‐free DNA testing and first‐trimester markers for pre‐eclampsia , 2018, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

[10]  M. Hestand,et al.  Fetal fraction evaluation in non-invasive prenatal screening (NIPS) , 2018, European Journal of Human Genetics.

[11]  L. Dugoff,et al.  Association of Fetal Fraction of Cell-Free DNA and Hypertensive Disorders of Pregnancy , 2018, American Journal of Perinatology.

[12]  Zhengfeng Xu,et al.  Perinatal outcomes following cell‐free DNA screening in >32 000 women: Clinical follow‐up data from a single tertiary center , 2018, Prenatal diagnosis.

[13]  A. McLennan,et al.  Implications of failure to achieve a result from prenatal maternal serum cell‐free DNA testing: a historical cohort study , 2018, BJOG : an international journal of obstetrics and gynaecology.

[14]  S. Kjaergaard,et al.  Contingent first‐trimester screening for aneuploidies with cell‐free DNA in a Danish clinical setting , 2018, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

[15]  J. Little,et al.  Comparison of first‐tier cell‐free DNA screening for common aneuploidies with conventional publically funded screening , 2017, Prenatal diagnosis.

[16]  M. Plana,et al.  Analysis of cell‐free DNA in maternal blood in screening for aneuploidies: updated meta‐analysis , 2017, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

[17]  Rafael Moreno-Luna,et al.  Total and Fetal Circulating Cell-Free DNA, Angiogenic, and Antiangiogenic Factors in Preeclampsia and HELLP Syndrome , 2017, American journal of hypertension.

[18]  R. Morris,et al.  Association of serum PAPP‐A levels in first trimester with small for gestational age and adverse pregnancy outcomes: systematic review and meta‐analysis , 2017, Prenatal diagnosis.

[19]  M. P. Koster,et al.  Absolute first trimester cell‐free DNA levels and their associations with adverse pregnancy outcomes , 2016, Prenatal diagnosis.

[20]  L. Dugoff,et al.  Cell-free DNA fetal fraction and preterm birth. , 2016, American journal of obstetrics and gynecology.

[21]  M. Watson,et al.  Noninvasive prenatal screening for fetal aneuploidy, 2016 update: a position statement of the American College of Medical Genetics and Genomics , 2016, Genetics in Medicine.

[22]  Y. Yaron.  The implications of non‐invasive prenatal testing failures: a review of an under‐discussed phenomenon , 2016, Prenatal diagnosis.

[23]  T. Loucks,et al.  Adverse perinatal outcomes are more frequent in pregnancies with a low fetal fraction result on noninvasive prenatal testing , 2016, Prenatal diagnosis.

[24]  A. Nasr,et al.  Circulating Maternal Total Cell-Free DNA, Cell-Free Fetal DNA and Soluble Endoglin Levels in Preeclampsia: Predictors of Adverse Fetal Outcome? A Cohort Study , 2016, Molecular Diagnosis & Therapy.

[25]  S. Warsof,et al.  Overview of the impact of noninvasive prenatal testing on diagnostic procedures , 2015, Prenatal diagnosis.

[26]  Sarah L. Kinnings,et al.  Factors affecting levels of circulating cell‐free fetal DNA in maternal plasma and their implications for noninvasive prenatal testing , 2015, Prenatal diagnosis.

[27]  T. Musci,et al.  Cell-free DNA analysis for noninvasive examination of trisomy. , 2015, The New England journal of medicine.

[28]  K. Nicolaides,et al.  Maternal plasma cell‐free DNA in the prediction of pre‐eclampsia , 2015, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

[29]  A. Siddiqui,et al.  Single-Nucleotide Polymorphism–Based Noninvasive Prenatal Screening in a High-Risk and Low-Risk Cohort , 2014, Obstetrics and gynecology.

[30]  L. Wilkins-Haug,et al.  Review: cell-free fetal DNA in the maternal circulation as an indication of placental health and disease. , 2014, Placenta.

[31]  J. Guerrero,et al.  Role of circulating cell-free DNA levels in patients with severe preeclampsia and HELLP syndrome. , 2013, American journal of hypertension.

[32]  A. Tabor,et al.  Identifying mild and severe preeclampsia in asymptomatic pregnant women by levels of cell‐free fetal DNA , 2013, Transfusion.

[33]  A. Oliphant,et al.  Gestational age and maternal weight effects on fetal cell‐free DNA in maternal plasma , 2013, Prenatal diagnosis.

[34]  J. Canick,et al.  The impact of maternal plasma DNA fetal fraction on next generation sequencing tests for common fetal aneuploidies , 2013, Prenatal diagnosis.

[35]  K. Nicolaides,et al.  Fetal fraction in maternal plasma cell‐free DNA at 11–13 weeks' gestation: relation to maternal and fetal characteristics , 2013, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

[36]  A. Tabor,et al.  High levels of fetal DNA are associated with increased risk of spontaneous preterm delivery , 2012, Prenatal diagnosis.

[37]  S. Hauguel-de Mouzon,et al.  Increased death of adipose cells, a path to release cell free DNA into systemic circulation of obese women , 2012, Obesity.

[38]  Z. Prohászka,et al.  Relationship of circulating cell-free DNA levels to cell-free fetal DNA levels, clinical characteristics and laboratory parameters in preeclampsia , 2009, BMC Medical Genetics.

[39]  J. Gabert,et al.  Total and Fetal Cell-Free DNA Analysis in Maternal Blood as Markers of Placental Insufficiency in Intrauterine Growth Restriction , 2009, Fetal Diagnosis and Therapy.

[40]  Michael Miller,et al.  Multiple splice defects in ABCA1 cause low HDL-C in a family with Hypoalphalipoproteinemia and premature coronary disease , 2009, BMC Medical Genetics.

[41]  R. Romero,et al.  High levels of fetal cell-free DNA in maternal serum: a risk factor for spontaneous preterm delivery. , 2005, American journal of obstetrics and gynecology.

[42]  K. C. Chan,et al.  Fetal DNA clearance from maternal plasma is impaired in preeclampsia. , 2002, Clinical chemistry.

[43]  T. Okai,et al.  Increased cell-free fetal DNA in plasma of two women with invasive placenta. , 2002, Clinical chemistry.

[44]  I. Sargent,et al.  Presence of fetal DNA in maternal plasma and serum , 1997, The Lancet.

[45]  R. Rava,et al.  Circulating fetal cell-free DNA fractions differ in autosomal aneuploidies and monosomy X. , 2014, Clinical chemistry.

[46]  P. Tugwell,et al.  The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses , 2014 .

[47]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. , 2010, International journal of surgery.

[48]  L. Hunt,et al.  Quantification of cell free fetal DNA in maternal plasma in normal pregnancies and in pregnancies with placental dysfunction. , 2009, American journal of obstetrics and gynecology.